WaveMan
WaveMan · Company
MYO · Myomo, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MYO Myomo (MYO) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001369290
Quote by TradingView
Form 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter

What the filings say about MYO

Insiders, 180 days
+$86.7K net bought
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$75.9K
4 notices

Myomo insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MYOMO, INC. insiders bought a net $86.7K of stock across 64 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kovelman Harry
Chief Medical Officer
SELL
2026-09-14 SECtraded 2026-09-11
15,488
$19.7K
-3.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 20, 2026.
  • The trade is 17.2% of the 90,245 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kovelman Harry sold about $19.7K of MYO on Sep 11, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Kovelman Harry
Chief Medical Officer
SELL
2026-10-15 SECtraded 2026-09-11
15,844
$20.1K
+0.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 20, 2026.
  • The trade is 17.6% of the 89,889 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kovelman Harry sold about $20.1K of MYO on Sep 11, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Morris Milton Mayo
Director
SELL
2026-09-04 SECtraded 2026-09-02
15,000
$21.1K
-10.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 8, 2023.
  • The trade is 7.2% of the 208,391 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morris Milton Mayo sold about $21.1K of MYO on Sep 2, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Kovelman Harry
Chief Medical Officer
SELL
2026-08-21 SECtraded 2026-08-20
17,250
$29.9K
-13.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 28, 2026.
  • The trade is 16.3% of the 105,983 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kovelman Harry sold about $29.9K of MYO on Aug 20, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Kovelman Harry
Chief Medical Officer
SELL
2026-08-24 SECtraded 2026-08-20
17,500
$30.3K
-18.9%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on May 28, 2026.
  • The trade is 16.6% of the 105,733 shares held after it.
  • 1 other insider sold within 30 days.
  • 49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Kovelman Harry sold about $30.3K of MYO on Aug 20, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 59 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$86.7K over 180 days
-$121.2K over 90 days
more than 72% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
49 funds bought in last quarter
below 58% of Medical Devices
Revenue
+25.7% year over year
more than 76% of Medical Devices
Margin
-38.1% net margin
below 64% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.8% of the float short (float per yahoo 2026-10-27) · 3.9 days to cover · settled 2026-10-15
below 56% of Medical Devices
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 15Chief Medical Officer Kovelman Harry sold $20.1K (Sep 11)
Oct 13Officer David Henry filed to sell $4.3K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch MYO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+14.3%12M
-39%-0%+38%+77%2025-102025-122026-022026-042026-062026-082026-10 2026-05-14 · Manko Joseph M. Jr. bought $146.9K2026-05-14 · Mitchell Micah sold $77.6K2026-03-13 · KIRK THOMAS F bought $51.1K2026-03-12 · Getz Heather C bought $51.1K2026-06-05 · KIRK THOMAS F bought $50.8K2026-05-18 · KIRK THOMAS F bought $39.5K2026-08-20 · Kovelman Harry sold $30.3K2026-08-20 · Kovelman Harry sold $29.9K2026-05-15 · KIRK THOMAS F bought $28.8K2026-05-15 · Manko Joseph M. Jr. bought $27.0K2026-05-28 · KIRK THOMAS F bought $24.8K2026-09-02 · Morris Milton Mayo sold $21.1K2026-05-27 · Kovelman Harry sold $20.5K2026-09-11 · Kovelman Harry sold $20.1K2026-09-11 · Kovelman Harry sold $19.7K2026-03-16 · Getz Heather C bought $14.0K2026-05-28 · Kovelman Harry sold $11.8K2025-11-20 · KIRK THOMAS F bought $3.5K2025-11-18 · Crowley Thomas Aloysius Jr. bought $2.9K2025-11-21 · KIRK THOMAS F bought $1.8K2025-11-19 · Crowley Thomas Aloysius Jr. bought $2962026-10-13 · David Henry filed to sell $4.3K2026-09-11 · HARRY KOVELMAN filed to sell $20.1K2026-09-02 · Morris Milton Mayo filed to sell $21.1K2026-08-20 · HARRY KOVELMAN filed to sell $30.3K2026-07-13 · David Henry filed to sell $5.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MYO: institutional holders (13F)

13F holdings, latest reported quarter
Rosalind Advisors, Inc.
3,637,886 sh
$3.8M
VANGUARD CAPITAL MANAGEMENT LLC
1,636,570 sh
$1.7M
AQR CAPITAL MANAGEMENT LLC
928,268 sh
$965.4K
Jefferies Financial Group Inc.
704,275 sh
$732.4K
JANE STREET GROUP, LLC
596,352 sh
$620.2K

Congress trades in MYO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MYO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
David Henry
Filed 2026-10-13
$4.3K
HARRY KOVELMAN
Filed 2026-09-11
$20.1K
Morris Milton Mayo
Filed 2026-09-02
$21.1K
HARRY KOVELMAN
Filed 2026-08-20
$30.3K
David Henry
Filed 2026-07-13
$5.6K

MYO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$34.6K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$196.7K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$14.4K position · as of 2026-05-31
0.0%
ProShares Russell 2000 High Income ETF
$1.8K position · as of 2026-05-31
0.0%
ProShares Ultra Russell2000
$1.4K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$238.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
-$348.6K
$649.0K
+78%
n/a
2024
$1.2M
$1.5M
$739.6K
+1159%
n/a
2023
$663.9K
$2.1M
$478.6K
+880%
n/a
2022
$526.0K
$179.6K
$352.9K
-93%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $86.7K bought by insiders over 180 days, 49 funds added last quarter, $75.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

MYO financials

Revenue growth
+25.7%
XBRL, annual
Net margin
-38.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$43.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-33.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$8.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.98x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Cash flow to debt
-0.62x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Return on equity
-124.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-39.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-45.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$47.8M
market value at close 2026-10-26 on 2026-07-31 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
-17.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$40.9M$32.6M$19.2M$15.6M
Gross profit$26.9M$23.2M$13.2M$10.3M
Operating income-$14.4M-$6.2M-$8.2M-$10.7M
Net income-$15.6M-$6.2M-$8.1M-$10.7M
EPS (diluted)-0.37-0.16-0.28-1.52
Operating cash flow-$14.5M-$3.3M-$6.2M-$10.2M
Cash$14.1M$24.4M$6.9M$5.3M
Long-term debt$11.2M$11.2Mn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

MYO Stock Sonar score 6/7 axes

Find similar shapesCompare

MYO ranks highest on growth (76th percentile) and insider conviction (72nd), and lowest on financial health (26th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
31
Inputs
  • Return on equity-124.0% · 24 pct, sector of 183
  • Return on assets-39.3% · 35 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-45.3% · 34 pct, sector of 188
Financial health
26
Inputs
  • Debt to equity1.98x · 13 pct, sector of 159
  • Cash flow to debt-0.62x · 40 pct, sector of 150
Growth
76
Inputs
  • Revenue growth, YoY+25.7% · 76 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d$87K · 71 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
42
Inputs
  • Funds adding, latest quarter49 · 42 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+3.8% · 55 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+16.5% · 25 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MYO filings, in plain words

Are Myomo insiders buying or selling MYO?

In the 180 days to 2026-10-28, Myomo insiders were net buyers, a net $86.7K: $317.7K of purchases and $231.0K of sales reported on Form 4, by 2 buyers and 3 sellers.

Are there planned insider sales of MYO?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $75.9K of stock; the latest, by David Henry, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-28, Myomo insiders were net buyers of MYO, a net $86.7K across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $75.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies